Journal of Medical Academics

Register      Login

VOLUME 2 , ISSUE 2 ( July-December, 2019 ) > List of Articles


Clostridioides difficile: An Overview of Current Diagnostic and Infection Prevention Modalities

Sachin Kishore, Priyanka Banerjee, Sanjay Singh Kaira

Keywords : Cell cytotoxicity neutralization assay, Clostridioides difficile infection, Enzyme immunoassays, Glutamate dehydrogenase, Nucleic acid amplification test, Toxigenic culture

Citation Information : Kishore S, Banerjee P, Kaira SS. Clostridioides difficile: An Overview of Current Diagnostic and Infection Prevention Modalities. Journal of Medical Academics 2019; 2 (2):61-64.

DOI: 10.5005/jp-journals-10070-0043

License: CC BY-NC 4.0

Published Online: 03-09-2020

Copyright Statement:  Copyright © 2019; The Author(s).


Clostridioides difficile, previously known as Clostridium difficile, has been recognized as an emerging nosocomial pathogen in recent years. Among hospitalized patients, it's a leading cause of increased mortality and morbidity. Earlier C. difficile infection (CDI) was not recognized for high morbidity and prolonged hospital stay. But, in last few decades due to uncontrolled usage of antibiotic and immunosuppressive drugs, CDI has increased in frequency and severity. Besides nonmodifiable risk factors, exposure to antibiotics is a single most modifiable risk factor. Various methods for diagnosis of CDI are known these days like toxigenic culture (TC) and cell cytotoxicity neutralization assay (CCNA), available only in reference laboratories. Other methods like enzyme immunoassays (EIA) for toxins A, B, and/or glutamate dehydrogenase (GDH) and nucleic acid amplification tests (NAATs) are routinely used for CDI diagnosis; however, each diagnostic test has some limitations. Early CDI diagnosis is critical for early treatment and effective infection control measures to reduce the morbidity and mortality and preventing outbreak. Poor infection control practices further contribute in spread of CDI and environmental contamination by spores of C. difficile. Therefore, a correct and authentic diagnostic modality that can be used to characterize CDI vs colonization and making an effective infection control policy for CDI are urgently needed for prevention of occurrence of CDI.

  1. Leffler DA, Lamont JT. Clostridioides difficile infection. N Engl J Med 2015;372(16):1539–1548. DOI: 10.1056/NEJMra1403772.
  2. Napolitano LM, Edmiston Jr. CE. Clostridioides difficile disease: Diagnosis, pathogenesis, and treatment update. Surgery 2017;162(2):325–348. DOI: 10.1016/j.surg.2017.01.018.
  3. Segar L, Easow JM, Srirangaraj S. Prevalence of Clostridioides difficile infection among the patients attending a tertiary care teaching hospital. Indian J Pathol Microbiol 2017;60(2):221–225. DOI: 10.4103/0377-4929.208383.
  4. Bartleft JG. Historical perspective on studies of Clostridioides difficile and C. difficile infection. Clin Infect Dis 2008;46(Suppl 1): S4–S11.
  5. Patel PV, Desai PB. Study of Clostridium difficile in south Gujarat region of india. Res J Recent Sci 2014;3(IVC-2014):34–41.
  6. Dubberke ER, Reske KA, Yan Y, et al. Clostridioides difficile—associated disease in a setting of endemicity: Identification of novel risk factors. Clin Infect Dis 2007;45(12):1543–1549. DOI: 10.1086/523582.
  7. Carey-Ann D, Diagnosis of Clostridioides difficile Infection: an Ongoing Conundrum for Clinicians and for Clinical Laboratories.
  8. Hensgens MP, Goorhuis A, Dekkers OM, et al. Time interval of increased risk for Clostridioides difficile infection after exposure to antibiotics. J AntimicrobChemother 2012;67(3):742–748.
  9. Pépin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridioides difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41(9):1254–1260. DOI: 10.1086/496986.
  10. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridioides difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. Cmaj 2005;173(9):1037–1042. DOI: 10.1503/cmaj.050978.
  11. Spigaglia P. Recent advances in the understanding of antibiotic resistance in Clostridioides difficile infection. Ther Adv Infect Dis 2016;3:23–42. DOI: 10.1177/2049936115622891.
  12. Vijay Kumar GS, Uma BM. Clostridium difficile: a neglected, but emerging pathogen in india. Arch Clin Microbiol 1989–8436;6(2):6.
  13. Debast SB, Bauer MP, Kuijper EJ. European society of clinical microbiology and infectious diseases: Update of the treatment guidance document for Clostridioides difficile infection. Clin Microbiol Infect 2014;20(Suppl. 2):1–26. DOI: 10.1111/1469-0691.12418.
  14. Peng Z, Ling L, Stratton CW, et al. Advances in the diagnosis and treatment of Clostridioides difficile infections. Emerg Microbes Infect 2018;7(1):15. DOI: 10.1038/s41426-017-0019-4.
  15. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridioides difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:431–455. DOI: 10.1086/651706.
  16. George WL, Sutter VL, Citron D, et al. Selective and differential medium for isolation of Clostridioides difficile. J Clin Microbiol 1979;9:214–219.
  17. Burnham CA, Carroll KC. Diagnosis of Clostridioides difficile infection: an ongoing conundrum for clinicians and for clinical laboratories. Clin Microbiol Rev 2013;26:604–630. DOI: 10.1128/CMR.00016-13.
  18. Dunwoody R, Steel A, Landy J, et al. Clostridioides difficile and cystic fibrosis: management strategies and the role of faecal transplantation. Paediatr Respir Rev 2017;26:16–18. DOI: 10.1016/j.prrv.2017.03.003.
  19. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridioides difficile infections. Am J Gastroenterol 2013;108:478–498. DOI: 10.1038/ajg.2013.4.
  20. Culbreath K, Ager E, Nemeyer RJ, et al. Evolution of testing algorithms at a university hospital for detection of Clostridioides difficile infections. J Clin Microbiol 2012;50(9):3073–3076. DOI: 10.1128/JCM.00992-12.
  21. Chen S, Gu H, Sun C, et al. Rapid detection of Clostridioides difficile toxins and laboratory diagnosis of Clostridioides difficile infections. Infection 2017;45(3):255–262. DOI: 10.1007/s15010-016-0940-9.
  22. Smits WK, Lyras D, Lacy DB, et al. Clostridioides difficile infection. Nat Rev Dis Primers 2016;2:16020. DOI: 10.1038/nrdp.2016.20.
  23. Martinez-Melendez A, Camacho-Ortiz A, Morfin-Otero R, et al. Current knowledge on the laboratory diagnosis of Clostridioides difficile infection. World J Gastroenterol 2017;23(9):1552–1567. DOI: 10.3748/wjg.v23.i9.1552.
  24. Polage CR, Gyorke CE, Kennedy MA, et al. Overdiagnosis of Clostridioides difficile infection in the molecular test era. JAMA Intern Med 2015;175(11):1792–1801. DOI: 10.1001/jamainternmed.2015.4114.
  25. Kociolek LK, Bovee M, Carter D, et al. Impact of a healthcare provider educational intervention on frequency of Clostridioides difficile polymerase chain reaction testing in children: a segmented regression analysis. J Pediatr Infect Dis Soc 2017;6(2):142–148.
  26. Crobach MJT, Planche T, Eckert C, et al. European society of clinical microbiology and infectious diseases: Update of the diagnostic guidance document for Clostridioides difficile infection. Clin Microbiol Infect 2016;22(Suppl. 4):S63–S81. DOI: 10.1016/j.cmi.2016.03.010.
  27. Erik R, Carling P, Carrico R, et al. Strategies to prevent Clostridioides difficile infections in acute care hospitals: 2014 Update. Infect Control Hosp Epidemiol 2014;35(6):628–645. DOI: 10.1086/676023.
  28. Boyce JM, Pittet D, Society for Healthcare Epidemiology of America, Association for Professionals in Infection Control, and Infectious Diseases Society of America. Guideline for hand hygiene in health-care settings: recommendations of the healthcare infection control practices advisory committee and the HICPAC/SHEA/APIC/IDSA hand hygiene task force. MMWR Recomm Rep 2002;51(RR-16):1–45. DOI: 10.1086/503164.
  29. Frequently asked questions about Clostridioides difficile for healthcare providers. Centers for Disease Control and Prevention website. 2005.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.